Trial · NCT01690052
Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
NCT01690052, Not applicable, Completed, University of Kentucky; results first posted 2014-08-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva. Trials, record NCT01690052. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01690052
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
- NCT number
- NCT01690052
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 15 participants, actual
- Lead sponsor
- University of Kentucky
- Conditions
- Dry Mouth
- Interventions
- Cevimeline, Pilocarpine
- First posted
- 2012-09-21
- Last updated
- 2018-06-04
- Results first posted
- 2014-08-06
- Limitations and caveats
- There are limitations that affected this study. This is a pilot study with a relative low number of patients.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Saliva Production in ml. | 4 weeks | The primary outcome measure was the change of stimulated and non-stimulated saliva in ml from the baseline record. At each appointment (weekly), participants will provide 2 saliva samples to measure their current salivary output. The first measurement will be obtained by having the patient spit as much as he or she could into a cup for five minutes. The amount of saliva in ml will be recorded. The second measurement will be obtained in a similar manner with the addition of having the patient chew on a block of unflavored wax. Patients will complete weekly questionnaires to help determine which side-effects they experience as they take the medications. |
| Other | Adverse Events | four weeks | Adverse events related to the combination and order of study medication will be measured |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Saliva Production in ml. | 4 weeks | ml | MEAN | |
| OTHER_PRE_SPECIFIED | Adverse Events | four weeks |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Saliva Production in ml. | Cevimeline | Unstimulated Saliva | 1.41 | Standard Deviation 0.5 | ml |
| Change From Baseline in Saliva Production in ml. | Pilocarpine | Unstimulated Saliva | 3.93 | Standard Deviation 0.5 | ml |
| Change From Baseline in Saliva Production in ml. | Cevimeline | Stimulated Saliva | 5.31 | Standard Deviation 0.5 | ml |
| Change From Baseline in Saliva Production in ml. | Pilocarpine | Stimulated Saliva | 10.34 | Standard Deviation 0.5 | ml |
Source ClinicalTrials.gov
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| FIRST INTERVENTION: 4 WEEKS | STARTED | Cevimeline First, Then Pilocarpine | 7 | |
| FIRST INTERVENTION: 4 WEEKS | STARTED | Pilocarpine First, Then Cevimeline | 8 | |
| FIRST INTERVENTION: 4 WEEKS | COMPLETED | Cevimeline First, Then Pilocarpine | 6 | |
| FIRST INTERVENTION: 4 WEEKS | COMPLETED | Pilocarpine First, Then Cevimeline | 6 | |
| FIRST INTERVENTION: 4 WEEKS | NOT COMPLETED | Cevimeline First, Then Pilocarpine | 1 | |
| FIRST INTERVENTION: 4 WEEKS | NOT COMPLETED | Pilocarpine First, Then Cevimeline | 2 | |
| Washout Period of 1 Week | STARTED | Cevimeline First, Then Pilocarpine | 6 | |
| Washout Period of 1 Week | STARTED | Pilocarpine First, Then Cevimeline | 6 | |
| Washout Period of 1 Week | COMPLETED | Cevimeline First, Then Pilocarpine | 6 | |
| Washout Period of 1 Week | COMPLETED | Pilocarpine First, Then Cevimeline | 6 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cevimeline Then Pilocarpine (Intervention 1) | 0 | 12 |
| Total, all-cause mortality | Pilocarpine Then Cevimeline (Intervention 2) | 0 | 12 |
| Total, other adverse events | Cevimeline Then Pilocarpine (Intervention 1) | 0 | 12 |
| Total, other adverse events | Pilocarpine Then Cevimeline (Intervention 2) | 0 | 12 |
| Total, serious adverse events | Cevimeline Then Pilocarpine (Intervention 1) | 0 | 12 |
| Total, serious adverse events | Pilocarpine Then Cevimeline (Intervention 2) | 0 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cevimeline Then Pilocarpine (Intervention 1) vs Pilocarpine Then Cevimeline (Intervention 2): deaths from any cause | Trial comparisons |
| Cevimeline Then Pilocarpine (Intervention 1) vs Pilocarpine Then Cevimeline (Intervention 2): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01690052
GET https://conductscience.org/api/trials/v1/NCT01690052/registered